Mabwell (Shanghai) Bioscience Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2017-05-12
- Employees
- 1.4K
- Market Cap
- -
- Website
- https://www.mabwell.com
Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: 9MW2921
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 261
- Registration Number
- NCT05990452
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Centel, Shanghai, China
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects
Phase 1
Recruiting
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Drug: 9MW3811 InjectionDrug: Placebo
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05912049
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Malignant Solid Tumor
- Interventions
- Drug: 9MW3811 Injection
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 27
- Registration Number
- NCT05911984
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
An Evaluation of 9MW1911 Injection in Healthy Subjects
Phase 1
Active, not recruiting
- Conditions
- AsthmaAtopic DermatitisCOPD
- Interventions
- Drug: Experimental drug 9MW1911Drug: Placebo
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05803902
- Locations
- 🇨🇳
Peking Union Hospital, Beijing, Beijing, China
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Malignant Solid Tumors
- Interventions
- Drug: 9MW2821
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05773937
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Beijing University Cancer Hospital, Beijing, Beijing, China
A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects
Phase 1
Recruiting
- Conditions
- TumorPulmonary Fibrosis
- Interventions
- Drug: 9MW3811 injectionDrug: Placebo
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05740475
- Locations
- 🇦🇺
Scientia Clinical Research, Randwick, New South Wales, Australia
6MW3511 in Patients With Advanced Solid Tumor
Phase 1
Not yet recruiting
- Conditions
- Solid Tumors
- Interventions
- Drug: Intravenous Infusion
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 272
- Registration Number
- NCT05524194
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
Phase 1
Recruiting
- Conditions
- Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- Drug: 6MW3211 injection with Intravenous Infusion
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05448599
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma
Phase 2
Not yet recruiting
- Conditions
- Lymphoma
- Interventions
- Drug: 6MW3211
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05446688
A Clinical Study of 6MW3211 in Patients With Renal Cancer
Phase 2
Not yet recruiting
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma
- Interventions
- Drug: 6MW3211
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05440045
© Copyright 2025. All Rights Reserved by MedPath